Domain Metastability: A Molecular Basis for Immunoglobulin Deposition?  by Sonnen, Andreas F.-P. et al.
doi:10.1016/j.jmb.2010.04.011 J. Mol. Biol. (2010) 399, 207–213
Available online at www.sciencedirect.comCOMMUNICATION
Domain Metastability: A Molecular Basis for
Immunoglobulin Deposition?
Andreas F.-P. Sonnen1⁎, Chao Yu2, Edward J. Evans2, David I. Stuart1,
Simon J. Davis2 and Robert J. C. Gilbert1⁎© 2010 Elsevier Ltd.Open access under CC BY license. 1Division of Structural Biology,
The Wellcome Trust Centre for
Human Genetics, University of
Oxford, Roosevelt Drive, Oxford
OX3 7BN, UK
2Nuffield Department of Clinical
Medicine and MRC Human
Immunology Unit, University of
Oxford, John Radcliffe Hospital,
Headington, Oxford OX3 9DU,
UK
Received 28 January 2010;
received in revised form
31 March 2010;
accepted 2 April 2010
Available online
13 April 2010*Corresponding authors.A.F.-P. Son
is to be contacted at Division of Stru
Wellcome Trust Centre for Human
University of Oxford, Roosevelt Dri
UK. E-mail addresses: andreas@stru
gilbert@strubi.ox.ac.uk.
Abbreviations used: IgSF, Ig supe
2,2,2-trifluoroethanol; PBS, phospha
0022-2836© 2010 Elsevier Ltd.Open acceWe present the crystal structure of an immunoglobulin light-chain-like
domain, CTLA-4, as a strand-swapped dimer displaying cis–trans proline
isomerisation and native-like hydrogen bonding. We also show that CTLA-
4 can form amyloid-like fibres and amorphous deposits explainable by the
same strand swapping. Our results suggest a molecular basis for the
pathological aggregation of immunoglobulin domains and why amyloid-
like fibres are more often composed of homologous rather than heterolo-
gous subunits.Keywords: CTLA-4; X-ray crystallography; protein aggregation assays;
electron microscopy; amyloidEdited by I. WilsonImmunoglobulin (Ig) light-chain protein deposi-
tion diseases arise when Ig domains form patholo-
gy-inducing aggregates; these can occur in a variety
of organs but most frequently in the kidney.1 The
molecular nature of the aggregates formed during
such disease processes has yet to be determined in
detail but two different kinds are known to exist:
amyloid-like fibres as found in light-chain amyloid-
osis and amorphous aggregates as found in light-
chain deposition disease.1 In the course of analyzing
the structure and interactions of CTLA-4, which is
providing important insights into avidity enhance-nen and R.J.C. Gilbert
ctural Biology, The
Genetics, The
ve, Oxford OX3 7BN,
bi.ox.ac.uk;
rfamily; TFE,
te-buffered saline.
ss under CC BY license. ment of regulatory signals at the T-cell surface,2–5
we crystallised and solved the structure of an
Escherichia coli-expressed monomeric form of the
protein (ecCTLA-4), which unexpectedly formed a
misfolded dimer and both amyloid and amorphous
aggregates under largely physiological conditions.
Our work provides new insights into the stability of
immunoglobulin folds and the process by which
they form disease-inducing amyloid-like deposits.
A monomeric form of ecCTLA-4, which comprises
a canonical Ig superfamily (IgSF) V-set domain, was
engineered by mutating the cysteine at position 122,
which forms a disulfide between the C-terminal
membrane-proximal linker regions of the protein, to
a serine. As expected, this construct was expressed
as a monomer (see Supplementary Fig. S1), and
its crystal structure revealed the characteristic
V-set IgSF fold (see Fig. 1a and Table 1). Although
only one molecule of CTLA-4 is present in each
crystallographic asymmetric unit, an unexpected
swapping of the C-terminal β-strands between
adjacent ecCTLA-4 molecules results in the
Fig. 1. Structure of a strand-swapped Ig-domain dimer. The structure of the stand-swapped dimer is shown in (a) and
its topological diagram in (b) (strands named according to standard conventions). For comparison, (c) displays the
topology diagram of the homodimeric maCTLA-4 ectodomain (Yu et al., manuscript in preparation). The location of the
disulfide is shown in yellow. The close-ups are molecular representations of the hinge regions (red boxes) in the swapped
(top, carbon in green, oxygen in red, nitrogen in blue and sulfur in yellow) and unswapped (bottom, same colours except
carbon in grey) vl-Ig domains. For purification of samples, see Supplementary Fig. S1 and Ref. 19; for structure
determination method and statistics for ecCTLA-4, see Table 1. (d) Omit map calculations for the structure. The hinge
region of the dimer was omitted in calculation of both the 2Fo−Fc map (blue) and the Fo−Fc map (green, at +3σ; red at
−3σ). The atomic model for one-half of the crystallographic dimer is included in the figure.
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Table 1
ecCTLA4
Data collection
Space group P3121
Cell dimensions
a, b, c (Å) 43.0, 43.0, 140.1
α, β, γ (°) 90, 90, 120
Resolution (Å) 18.6–2.6
Rmerge 3.6 (20.0)
I/σI 29.1 (9.0)
No. of reflections/no. unique 99,136/4488
Completeness (%) 85.0 (45.8)
Redundancy 22.1 (21.3)
Refinement
Resolution (Å) 18.6–2.6
No. of reflections 4289
Rwork/Rfree 19.2/24.5⁎
No. of atoms
Protein 914
Water 50
B-factors
Protein (main chain) 26.6
Protein (side chain) 31.1
Water 22.1
Overall 28.4
R.M.S.D.s
Bond lengths (Å) 0.006
Bond angles (°) 1.03
Ramachandran plot analysis
Outliers 0.00%
In allowed regions 4.31%
In preferred regions 95.69%
The CTLA4 vl-Ig was concentrated to 10 mg/ml in Hepes-
buffered saline at pH 7.4 and crystallised in 0.02 M magnesium
chloride, 0.1 M Hepes (pH 7.5), 22% (w/v) polyacrylic acid 5100
sodium salt and 0.4 M NDSB-256 (nondetergent sulfobetaine 256,
dimethylbenzylammonium propane sulfonate), or with 6% 1,6-
diaminohexane. Crystals appeared after 12 h and were frozen in a
stream of nitrogen either with perfluorated oil or with 25%
glycerol in the mother liquor as cryoprotectant. Data were
collected on a MAR345 in-house detector at a wavelength of
1.542 Å. Data were indexed, integrated and scaled with the XDS
package21 and the structure was solved bymolecular replacement
using PHASER22 with monomeric CTLA4 (Protein Data Bank
code 1I8L, the structure of CTLA4 from the complex with B7-13).
The structure was refined with Refmac5.423 using a maximum
likelihood target alternated with manual rebuilding of the
structure (⁎4.2% of the reflections have been used for Rfree
calculation, i.e., 189 reflections). Parenthetical values are for the
highest-resolution shell.
209Molecular Basis for Immunoglobulin Depositionformation of an artificial homodimer (compare the
topology diagrams in Fig. 1b and c). In Fig. 1d we
show an omit map with phase information for the
strand-swapped region excluded from the calcula-
tion: the 2Fo−Fc map shows clearly the strand-
swapped density. The GG′ strands of one domain
replace the GG′ strands of a neighbour, and vice
versa, forming a compact dimeric unit. A structural
comparison with the native, non-strand-swapped
crystal structures of B7-complexed CTLA-43 and
mammalian-expressed CTLA-4 (maCTLA-4; Yu et
al., manuscript in preparation) which forms a quite
different disulfide-linked dimer, revealed that cis–
trans isomerisation of the prolines at positions 101
and 103 relieves peptide bond strain in ecCTLA-4
seemingly driving the strand swap of the C-terminal
β-strands (Fig. 1b and c). In Supplementary Fig. S2,
we show a superposition of all four previouslydetermined CTLA-4 crystal structures—three of
which describe non-strand-swapped dimers (all
additionally ligand bound)2,3,6 and one of which is
an unliganded monomer.7 In addition to superposi-
tion of the domains themselves, we show a close-up
of the triproline loop in which cis–trans isomerisa-
tion is present in the ecCTLA-4 structure compared
to the others. As well as this reconfiguration, new
van der Waals and hydrogenbonding interaction
networks between the amino acids forming the
(opened) hinging region appear to provide stabilisa-
tion energy for the strand-swapped ecCTLA-4
dimer, alongside the formation of the native-like β-
strand interactions between the GG′ and F strands.
The strand swap seen in our CTLA-4 structure is
strikingly similar to that found for CD478 and also
that seen for a llama antibody variable heavy chain,9
which was hypothesised to provide a basis for
understanding aggregation by Ig domains.1 To
investigate the possibility that the strand swapping
we observe could underpin additional levels of
aggregation, we incubated a concentrated solution
of monomeric ecCTLA-4 at room temperature for
24 h, whereupon dimeric and larger oligomeric
species formed (Supplementary Fig. S3). This
indicates that purified monomeric ecCTLA-4 ecto-
domain can refold to a relatively stable strand-
swapped dimer and also produce larger aggregates.
To unravel the structural basis of immunoglobulin
domain aggregation, and in particular to investigate
the bimodal and concurrent formation of both fibres
and amorphous aggregates, we investigated ecC-
TLA-4 aggregation further.
To assess the amyloid-forming propensity of the
monomeric and strand-swapped dimeric forms of
CTLA-4, we employed an assay established by
Wright et al. in which 2,2,2-trifluoroethanol (TFE)
is used to create mildly denaturing conditions and
so stimulate aggregation.10 Both the monomeric,
refolded protein and the dimeric material produced
by overnight incubation formed aggregates, the
kinetics of which could be followed by monitoring
the fluorescence of the amyloid-specific dye Thio-
flavin T. This suggests that the higher-order aggre-
gates have an amyloid-type structure (see Fig. 2a).
The rate at which aggregation occurred was
comparable to that observed for other amyloido-
genic proteins.10,11 The aggregates formed were also
Congo Red-positive (see Fig. 2b), which is another
indicator of amyloid-type structure. In the case of
the maCTLA-4 ectodomain retaining its cysteine-
containing C-terminus, the C-terminal β-strands of
the homodimer appear to be prevented from strand
swapping by disulfide bond formation, since this
form of the protein exhibited no tendency to form
aggregates, even in the presence of TFE (see Fig. 2a).
This indicates that a free C-terminus, and thus also a
less constrained hinging region, mediates strand
swapping and amyloid-type aggregate formation.
Furthermore, it implies that a fundamental meta-
stability within the IgSF V-set fold allows strand
swapping in soluble forms of CTLA-4 that is likely
to be prevented by membrane anchoring and/or
210 Molecular Basis for Immunoglobulin Depositiondisulfide formation in full-length protein or the
wild-type ectodomain. Aggregates of ecCTLA-4
could bind Thioflavin T (see Supplementary Fig.
S4), but their capacity to do so did not increase upon
additional incubation with TFE (see Fig. 2a). Thus
ecCTLA-4 monomers seem to become kinetically
trapped as strand-swapped dimers that, along with
monomers, can then convert to thermodynamically
more stable higher-order aggregates, but the aggre-
gates themselves represent a distinct and terminally
misfolded form of the protein.Fig. 2 (legend oWhat is the molecular nature of these aggre-
gates? The ultrastructure was visualised by nega-
tive stain electron microscopy and is displayed in
Fig. 2c. In addition to an apparently amorphous
aggregate, individual fibres could be imaged that
appear to consist of “beads-on-a-string” type
structures similar to those described by Bennett
et al.1 This linear, one-dimensional polymerisation
would propagate as each monomer forms a
strand-accepting surface (the interface that coordi-
nates the GG′ strands in the native domain) byn next page)
Fig. 3. A schematic of CTLA-4 self-association. (a) Schematic of the native, membrane-bound disulfide-bonded CTLA-
4 dimer on a membrane (wavy line), (b) the dimeric structure reported here (compare Fig. 1a), and (c) a possible
arrangement of five subunits within a CTLA-4 amyloid fiber according to a matching strand swapping.
211Molecular Basis for Immunoglobulin Depositiondonating its GG′ strands to a neighbour. Consis-
tent with such an arrangement for the CTLA-4
aggregates, circular dichroism (CD) indicates that
the secondary structure of the soluble protein and
that of the aggregates are very similar (Fig. 2d).
The prominent spectral minimum at a wavelength
of around 220 nm is characteristic for β-sheet
structures and differences in the fine structure of
the aggregate scan are indicative of structural
rearrangement upon amyloid formation, without a
change in the secondary structure. The CD
spectrum of the monomer also shows that CTLA-
4 was folded prior to crystallisation and that a
(partially) unfolded structure, due to the presence
of residual unfolding agents for instance, was not
responsible for strand swapping.
When calculating the strand-swapping capacity
of the IgSF domain as defined by Bennett et al.,1 itFig. 2. Amyloid formation by an Ig domain. (a) Monomeri
24 h at room temperature. The solution was then applied to a s
dimeric species as well as higher molecular weight species and a
Under the strong denaturing (but not reducing) conditions in
weights that corresponded to the monomer were found (see Su
mass spectrum is shown). To further assay the aggregation, it
saline (PBS) with 28% TFE and the scatter of light at 400 nm w
formation was followed by monitoring the scattering of 400 nm
for monomer (orange), strand-swapped dimer (green), higher
(grey) upon incubation with TFE. Optical density (OD) and fluo
fluorescence measurements, see Supplementary Fig. S4. (b) Con
(50 μl) were placed on a clean microscope slide and dried unde
filtered several times through a 0.22-μm nucleopore filter and
coverslip was placed onto the sample, which was then dried wi
with nail varnish. The sample was imaged under normal and cro
microscope fitted with a charge-coupled device camera. Here
(top) and the same field of viewwith crossed-polarising filters in
bar indicates a length of 50 μm in both panels. (c) Electronmicros
a benchtop centrifuge and stained with 1% uranyl acetate on ca
were imaged on Kodak SO-163 film with a Tecnai F30 electron
Here we show an electron micrograph of negatively stained a
close-up of an individual strand (bottom) shows the apparently b
UV CDmeasurements were performed with a Chirascan spectr
quartz cuvette at a concentration of 20 μM protein. Measurem
aggregate formation and after aggregate formation. The obtain
according to the equation h½  = h10 × c × l, where c is the concentra
the cuvette. A CD spectrum ofmonomeric ecCTLA4 is shown (to
(bottom). The prominent minimum around 220 nm is ind
Supplementary Fig. S3 for assessment of protein aggregate formbecomes clear that the monomer can only interact
with two additional protomers and hence can only
form a linear arrangement. As seen for sickle cell
haemoglobin,12 the cross-β-spine of archetypal
amyloid fibrils is not essential for producing
large fibres that may be involved in disease
manifestation, and structures with native-like
folds can lead to disease phenotypes; the native
fold would also be preserved in a bead-like
arrangement of the CTLA-4 V-set domains in
fibres, as shown schematically in Fig. 3. Similar
strand swapping mediates a family of diseases
known as serpinopathies in which non-amyloid-
type fibres are formed.1
Domain swapping of the type we have observed
provides an explanation for the observation made
by Wright et al. that immunoglobulin domains of
similar sequence aggregate much faster and to ac CTLA4 was concentrated to 10 mg/ml and incubated for
ize-exclusion chromatography column whereupon a stable
ggregates could be separated (see Supplementary Fig. S3a).
electrospray ionization mass spectrometry only molecular
pplementary Fig. S3b, where a representative deconvoluted
was induced by incubating CTLA4 in phosphate-buffered
as followed in real time (see Refs. 10 and 20). Aggregate
light (top) and Thioflavin T fluorescence increase (bottom)
-order aggregate (blue) and disulfide-bonded maCTLA-4
rescence are reported in arbitrary units (a.u.). For details of
go Red staining of amyloid fibrils. CTLA-4 amyloid fibrils
r air. A 10 μM solution of Congo Red in PBS at pH 7.4 was
50 μl was added onto the dried amyloid fibrils. A clean
th a paper towel and sealed along the edges of the coverslip
ssed-polarised light with aNikon Eclipse TE2000U inverted
we show aggregates imaged under bright-field conditions
troduced above and below the specimen (bottom). The scale
copy of CTLA-4 aggregates. Aggregateswere spundown in
rbon-coated electron microscopy copper grids. The samples
microscope (FEI) operating at 300 kV accelerating voltage.
ggregate; stranded structures can clearly be discerned. The
ead-like arrangement of the Ig domains in the fibril. (d) Far-
ophotometer (Applied Photophysics) in a 1-mm path-length
ents were conducted in PBS (pH 7.5) for the CTLA4 before
ed ellipticities, θ, were converted to molar ellipticities, [θ],
tion of CTLA-4 in monomer units and l is the path length of
p) and a CD spectrum of ecCTLA-4 after amyloid formation
icative of β-strand secondary structural elements. See
ation and the absence of disulfide bonds.
212 Molecular Basis for Immunoglobulin Depositiongreater extent into amyloid-like structures than
domains of dissimilar sequence: swapping β-
strands of dissimilar sequences would effect imper-
fect structural complementation and decreased
stability.10 Our observations also support the
proposal1 that domain swapping could be the
molecular basis for the formation of both fibrils
and aggregates in the same disease, especially when
different kinds of deposits arise from the same
protein. In certain lymphoproliferative disorders,
immunoglobulin domains are overproduced, result-
ing in amorphous and fibrillar aggregates. A soluble
splice-variant form of CTLA-4 that lacks the
transmembrane region and membrane-proximal
linker has been identified in vivo, being most
abundant in bone marrow, blood and lymph
nodes.13 This naturally soluble form of CTLA-4
formed dimeric species with apparently comparable
stability to that of the dimer described here, as well
as some higher molecular weight aggregates. In
patients with autoimmune thyroid disease, the
levels of expression of soluble CTLA-4 are as much
as 7- to 20-fold greater than in normal individuals;14
furthermore, individuals suffering from myasthenia
gravis,15 systemic lupus erythematosus16 and sys-
temic sclerosis17 also show elevated soluble CTLA-4
expression. Indeed, in systemic sclerosis the level of
CTLA-4 expression appears linked to adverse
progression, and aggregated protein deposits are
associated with pathology.17
It is noteworthy that the two-β-sheet DEBA–GFCC′
C″ topology characteristic of IgSF domains appears
independently in cytokine receptors, fibronectin,
cadherins, transcription factors and bacterial cytosolic
domains, indicating that it is among the most
successful folding topologies. In spite of this, there
are now four examples of IgSF domains exhibiting
intrinsic metastability: CTLA-4, CD47, the llama
antibody heavy chain and CD2.8,9,18 In the case of
theCD2dimer, amuchmore dramatic rearrangement
is observed, inwhich theA, B, C andC′ strands of one
polypeptide combinewith theD, E, F andG strands of
the other. It seems that the evolution of these proteins
accommodated a trade-off between facile folding and
potentially disease-causing metastability.Protein Data Bank accession code
Coordinates and structure factors for the ecCTLA-
4 strand-swapped dimer have been deposited with
Protein Data Bank accession code 2x44.Acknowledgements
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